Here are the 10-Q quarterly reports from ProtoKinetix Inc (PKTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PKTX filings page.
ProtoKinetix, Inc. (PKTX) reported a net loss of $77,726 for the three months ended March 31, 2026, compared with $97,690 a year earlier. The development-stage medical research company says it has not developed a commercially viable product or generated significant revenue. Research and development expense was $24,220, versus $33,810, and net cash used in operating activities was $23,616, versus $51,970.
Cash was $524 and working capital was negative $235,879 at March 31, 2026. Management said additional equity and/or debt financing is required to meet cash-flow projections and continue business objectives; the company disclosed substantial doubt about its ability to continue as a going concern. Disclosure controls were ineffective as of November 4, 2026. After quarter-end, it issued convertible notes for the purchase of 16,540,000 common shares, with gross proceeds of $165,400. On April 30, 2026, it issued 2,100,000 shares in a private placement for gross proceeds of $21,000. ProtoKinetix formed SightPath Biotech LLC on February 11, 2026, to develop PKX-001 for dry-eye and other ocular diseases; the subsidiary had no operating activity.
ProtoKinetix (PKTX) filed its Q3 2025 10‑Q, reporting a net loss of $84,906 for the quarter and $273,663 for the nine months. The company ended the period with $607 in cash, total assets of $477,623, liabilities of $227,196, and stockholders’ equity of $250,427.
To fund operations, ProtoKinetix completed small private placements in 2025: 17,700,000 units for $172,500 cash plus $4,500 in services, and 500,000 shares for $5,000. Between July 25 and September 25, it issued 1,000,000 shares for $10,000. Options outstanding were 94,790,000 and warrants outstanding were 23,700,000 as of September 30, 2025. As of November 13, 2025, 391,580,152 common shares were outstanding.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and stated disclosure controls and procedures were not effective as of September 30, 2025. Stockholders approved an amendment increasing authorized common shares from 500,000,000 to 600,000,000.